Targeting trafficking in drug development
Author(s)
Bibliographic Information
Targeting trafficking in drug development
(Handbook of experimental pharmacology, 245)
Springer, c2018
Available at 5 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographical references
Description and Table of Contents
Description
Cellular trafficking is only recently identified as a site for therapeutic intervention. This book provides up to date information on the mechanism for exploiting this area for drug development as well as a clear understanding of the individual components of cellular trafficking. The authors are experts in their areas and the book features tables and figures that enable comparison and clear understanding.
Table of Contents
Preface1. Intracellular trafficking of gonadotropin receptors in health and disease. (Ulloa-Aguirre et al)2. Investigating internalization and intracellular trafficking of GPCRs. (Simon R. Foster and Hans Brauner-Osborne) 3. Pharmacological chaperones as potential therapeutic strategies for misfolded mutant vasopressin receptors. (Bernard Mouillac and Christiane Mendre)4. Targeting of disordered proteins by small molecules in neurodegenerative diseases. (Francesca Longhena, PierFranco Spano, Arianna Bellucci5. Pharmacoperones for misfolded gonadotropin receptors. (Claire L. Newton and Ross C. Anderson)6. Pharmacological chaperones: Beyond conformational disorders. (Nancy J. Leidenheimer)7. Natural (and unnatural) small molecules as pharmacological chaperones and inhibitors in cancer. Isabel Betancor, (David J. Timson, Eduardo Salido, Angel L. Pey)8. Heritable skeletal disorders arising from defects in processing and transport of Type I procollagen from the ER: perspectives on possible therapeutic approaches. (Meritxell B. Cutrona, Niamh E. Morgan, Jeremy C. Simpson)9. Conserved oligomeric Golgi and neuronal vesicular trafficking. (Leslie K. Climer, Rachel D. Hendrix, Vladimir V. Lupashin)10. SLC6 transporter folding diseases and pharmacochaperoning. (Michael Freissmuth, Thomas Stockner, Sonja Sucic)11. The molecular physiopathogenesis of islet amyloidosis. (Diti Chatterjee Bhowmick, Sanghamitra Singh, Saurabh Trikha, Aleksandar M. Jeremic)12. Folding defects leading to primary hyperoxaluria. (Elisa Oppici, Mirco Dindo, Carolina Conter, Carla Borri Voltattorni, Barbara Cellini)13. Potential pharmacological chaperones for cystathionine beta-synthase-deficient homocystinuria. (Tomas Majtan, Angel L. Pey, Paula Gimenez-Mascarell, Luis Alfonso Martinez-Cruz, Csaba Szabo, Victo Kosich, Jan P. Kraus)
by "Nielsen BookData"